Safety of incremental inhaled lipopolysaccharide challenge in humans

John S Sundy; William A Wood; Janet L Watt; Joel N Kline; David A Schwartz

doi:10.1177/09680519060120020701

Back

Safety of incremental inhaled lipopolysaccharide challenge in humans

Journal article

Open access

Safety of incremental inhaled lipopolysaccharide challenge in humans

John S Sundy, William A Wood, Janet L Watt, Joel N Kline and David A Schwartz

Journal of endotoxin research, Vol.12(2), pp.113-119

04/2006

DOI: 10.1177/09680519060120020701

PMID: 16690014

Files and links (1)

url

https://doi.org/10.1177/09680519060120020701View

Published (Version of record) Open Access

Abstract

Background: Inhalation of environmental endotoxin is important in the pathogenesis of asthma and other environmental airway diseases. Inhaled airway challenge using lipopolysaccharide in humans has been performed for over 20 years to assess the airway response to endotoxin. However, there are no published data on the short-term safety of endotoxin inhalation protocols. Objective: To characterize the safety and tolerability of incremental inhaled lipopolysaccharide challenge in humans. Patients and Methods : We performed a retrospective analysis of data obtained from 119 subjects who underwent inhaled challenge with up to 41.5 µg of lipopolysaccharide. We measured pulmonary function, temperature, mean arterial pressure, heart rate, and systemic symptoms for 3 h after challenge. Results: Fever occurred in 30% of subjects and was associated with a higher cumulative dose of lipopolysaccharide. Reduced mean arterial pressure occurred in 21% of subjects and was dose-related. There was no association between fever or decreased mean arterial pressure and airway responsiveness to inhaled lipopolysaccharide. Common symptoms reported by subjects included: chills (64%), malaise (56%), cough (56%), chest tightness (49%), headache (43%), and myalgias (27%). None of the subjects experienced delayed discharge or a serious adverse event. Conclusions: Inhaled lipopolysaccharide causes dose-related systemic responses that include fever, reduced blood pressure, and constitutional symptoms that are not associated with the airway response to inhaled lipopolysaccharide. Systemic responses to inhaled lipopolysaccharide should be expected and subjects undergoing inhaled lipopolysaccharide challenge in the research setting should be carefully monitored for non-pulmonary adverse events for several hours after challenge.

Lipopolysaccharide

systemic responses

endotoxin

inhalation challenge

Details

Title: Subtitle: Safety of incremental inhaled lipopolysaccharide challenge in humans
Creators: John S Sundy - Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
William A Wood - Harvard Combined Medicine/Pediatrics Training Program, Massachusetts General Hospital, Boston, Massachusetts, USA
Janet L Watt - Department of Medicine, University of Iowa, Iowa City, Iowa, USA
Joel N Kline - Department of Medicine, University of Iowa, Iowa City, Iowa, USA
David A Schwartz - Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
Resource Type: Journal article
Publication Details: Journal of endotoxin research, Vol.12(2), pp.113-119
DOI: 10.1177/09680519060120020701
PMID: 16690014
NLM abbreviation: J Endotoxin Res
ISSN: 0968-0519
Publisher: Sage Publications
Language: English
Date published: 04/2006
Academic Unit: Pulmonary, Critical Care, and Occupational Medicine; Occupational and Environmental Health; Internal Medicine
Record Identifier: 9984094659302771

Metrics

10 Record Views

7 Times Cited - Web of Science